Table 2. Table.
| Unadjusted HR (95% CI)* | p-value | Model 1 HR (95% CI)* | p-value | Model 2 HR (95% CI)† | p-value | Model 3 HR (95% CI)§ | p-value | ||
|---|---|---|---|---|---|---|---|---|---|
| Medical treatment group | |||||||||
| qn-HRP and ql-HRP | None | Reference | NA | Reference | NA | Reference | NA | Reference | NA |
| Either | 1.48 (0.61-3.59) | 0.384 | 1.50 (0.60-3.75) | 0.383 | 1.55 (0.61-3.92) | 0.357 | 1.50 (0.62-3.60) | 0.368 | |
| Both | 8.36 (2.86-24.44) | <0.001 | 8.73 (2.86-26.62) | <0.001 | 8.56 (2.83-25.90) | <0.001 | 7.82 (2.80-21.87) | <0.001 | |
| PCI group | |||||||||
| qn-HRP and ql-HRP | None | Reference | NA | Reference | NA | Reference | NA | Reference | NA |
| Either | 0.66 (0.15-2.89) | 0.581 | 0.51 (0.11-2.28) | 0.380 | 0.79 (0.19-3.34) | 0.753 | 0.73 (0.16-3.38) | 0.683 | |
| Both | 0.81 (0.20-3.37) | 0.774 | 0.69 (0.16-3.05) | 0.624 | 1.08 (0.27-4.36) | 0.917 | 0.93 (0.25-3.48) | 0.909 | |
| This analysis was done in the whole population (n=697). *Model 1: adjusted for male, hyperlipidaemia, and acute coronary syndrome. †Model 2: adjusted for the use of aspirin, P2Y12 inhibitor, and statin. §Model 3: adjusted for LAD, % diameter stenosis, FFR, and LAP volume. CI: confidence interval; FFR: fractional flow reserve; HR: hazard ratio; HRP: high-risk plaque; LAD: left anterior descending artery; LAP: low-attenuation plaque; NA: not available; PCI: percutaneous coronary intervention; ql-HRP: qualitative HRP; qn-HRP: quantitative HRP; VOCO: vessel-oriented composite outcome | |||||||||